A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Trial Profile

A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Sep 2015

At a glance

  • Drugs Milatuzumab-doxorubicin conjugate (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 04 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 07 May 2014 Trial status changed from suspended to recruiting as reported by ClinicalTrials.gov.
    • 18 Jun 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top